New Keytruda Combo Wins Funding In England For NSCLC
Executive Summary
MSD’s Keytruda will be paid for through the Cancer Drugs Fund for use in combination with carboplatin and paclitaxel as a first-line treatment for metastatic squamous non-small-cell lung cancer.